News & Updates
SOLVD Health’s Pharmacogenomics Test Receives New York State Department of Health Approval
December 17, 2025 — SOLVD Health, a patient intelligence company pioneering precision medicine through advanced genetics and AI-driven insights, announced today that its pharmacogenomics (PGx) test PreScript™ has received approval from the New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP). This milestone enables SOLVD Health to offer its PGx testing services to healthcare providers and patients across New York State, one of the most rigorously regulated laboratory markets in the nation.
SOLVD Health Publishes Peer-Reviewed Framework to Advance Clinical Use of Genomic Data
December 15, 2025 — SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has published a peer-reviewed article in the International Journal of Molecular Sciences on best practices for the clinical use of genome-wide association study (GWAS) data. The article provides guidance for integrating imputed genetic information into healthcare in a way that supports accuracy, transparency, and clinical utility.
SOLVD Health Advances Development of Novel Test to Optimize GLP-1 Therapeutic Response
December 9, 2025 – SOLVD Health is launching two studies to validate our GLP‑1 patient stratification platform, bringing precision medicine to obesity and type 2 diabetes care. “As the worldwide prevalence of obesity and type 2 diabetes continues to grow, the need for more targeted, personalized treatment methods becomes increasingly critical,” Dr. Keri Donaldson, Founder and President, SOLVD Health.
SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth
May 12, 2025 – SOLVD Health appoints diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company’s continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform.
SOLVD Health Receives New York State Laboratory Approval
December 24, 2024 – SOLVD Health announces approval from the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) for its San Diego-based laboratory.
SOLVD Health to Present at William Blair’s Innovator Series
December 10, 2024 — SOLVD Health announces that its Founder and CEO, Dr. Keri Donaldson, will provide a company update and participate in a virtual fireside chat at William Blair’s Innovator Series: Life Science Tools and Diagnostics.
SOLVD Health Launches 5-Year Post-Approval Study on Real-World Impact for AvertD® Genetic Test
November 18, 2024 — SOLVD Health has launched a comprehensive post-approval study for AvertD®, the first U.S. Food and Drug Administration (FDA)-approved genetic test for assessing risk of developing opioid use disorder (OUD). This study aims to expand upon pivotal study findings and further demonstrate AvertD’s ability to enhance personalized data-driven decisions in real-world settings.
SOLVD Health Receives FDA PMA Supplement Approval for Use of INFINITI High-Throughput System with AvertD®
November 12, 2024 — SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has received U.S. Food and Drug Administration (FDA) PMA supplement approval for its INFINITI High Throughput System (HTS) to be used with AvertD®.
SOLVD Health Names Chief Financial Officer and Senior Vice President of Clinical Operations
August 13, 2024 — SOLVD Health, a patient intelligence company focused on creating innovative technologies that identify an individual’s risk of disease by discovering and converting biological signals into predictive, contextual health insights, has appointed Mark Hazeltine as Chief Financial Officer and Ron McCullough as Senior Vice President of Clinical Operations.
FDA Approves First Test to Help Identify Elevated Risk of Developing Opioid Use Disorder
December 19, 2023 — Today, the U.S. Food and Drug Administration approved the first test that uses DNA in assessing whether certain individuals may have an elevated risk of developing opioid use disorder (OUD).